Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab
David A Bond, Lapo Alinari Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA Abstract: Classical Hodgkin’s lymphoma (cHL) is a B-cell malignancy comprised of patho...
Main Authors: | Bond DA, Alinari L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-05-01
|
Series: | Journal of Blood Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/emerging-treatment-options-for-the-management-of-hodgkins-lymphoma-cl-peer-reviewed-article-JBM |
Similar Items
-
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
by: Lorenzo Falchi, et al.
Published: (2016-11-01) -
Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01) -
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01) -
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
by: Oncale MB, et al.
Published: (2017-02-01) -
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
by: Theodoros P. Vassilakopoulos, et al.
Published: (2019-07-01)